WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy

Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome

(2009) Masaki Yasukawa et al.   AMERICAN JOURNAL OF HEMATOLOGY

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

(2009) U. Keilholz et al.   BLOOD

CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT

(2009) M Kapp et al.   BONE MARROW TRANSPLANTATION

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor

(2009) Yusuke Oji et al.   INTERNATIONAL JOURNAL OF CANCER

Identification of a WT1 protein-derived peptide, WT1187, as a HLA-A*0206-restricted, WT1-specific CTL epitope

(2009) Zheyu Li et al.   MICROBIOLOGY AND IMMUNOLOGY

WT1 (WILMS TUMOR 1) PEPTIDE IMMUNOTHERAPY FOR CHILDHOOD RHABDOMYOSARCOMA: A Case Report

(2009) Hideaki Ohta et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme

(2008) Shuichi Izumoto et al.   JOURNAL OF NEUROSURGERY

A WT1 protein-derived, naturally processed 16-mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4+T cells

(2008) Fumihiro Fujiki et al.   MICROBIOLOGY AND IMMUNOLOGY